Dr Taub and Dr Patel discuss how to assess for cardiovascular risk in your patients.
Expanding Horizons on Who can Benefit from Non-Statin LDL-Cholesterol Lowering Therapy for Cardiovascular Risk Reduction
Dr Taub discusses how to match the intensity of lipid lowering therapy to the assessed cardiovascular risk.
Expert cardiologists discuss if there is such a thing as an LDL that is a too low.
Dr Taub and Dr Patel discuss which non statin agents are available for LDL-C lowering.
Expert cardiologists describe the importance of combination therapy for hyperlipidemia in high risk patients
Dr Taub describes effective strategies in overcoming access barriers to novel lipid lowering therapies.
Expert cardiologists discuss the cumulative burden of an elevated cholesterol over time.
Dr Kohli gives an overview of the mechanisms of action of non-statin agents for the management of hyperlipidemia.
Expert cardiologists discuss the recent clinical trials results of the CLEAR-OUTCOMES trial and thee sub analysis on the inflammatory marker hcCRP.
Cardiologists discuss how to select the right treatment for your patient with hyperlipidemia
Dr Taub, Dr Patel, and Dr Kohli look ahead to the future of the management of cardiovascular risk and hyperlipidemia
Advertisement
Advertisement
Trending on HCPLive
1
Chronic Hypoparathyroidism Today: Unmet Needs, Conventional Therapy Limits, and the Shift to PTH Replacement
2
Elafibranor Achieves 85% ALP Normalization in Phase 3b ELSPIRE Trial for PBC
3
SIGNAL-AA: Bempikibart Effective for Alopecia Areata at 36 Weeks
4
Avapritinib 4-Year PIONEER Data: Sustained QoL Gains in ISM
5